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Abstract A family history of prostate cancer (PCa) is an
established risk factor for PCa. In case of a positive family
history, the balance between positive and adverse effects of
prostate-speciﬁc antigen (PSA) testing might be different
from the general population, for which the European
Randomized Study of Screening for Prostate Cancer
(ERSPC) showed a beneﬁcial effect on mortality. This,
however, went at the cost of considerable overtreatment.
This study assessed Dutch physicians’ knowledge of
heredity and PCa and their ‘post-ERSPC’ attitude towards
PCa testing, including consideration of family history. In
January 2010, all Dutch urologists and clinical geneticists
(CGs) and 300 general practitioners (GPs) were invited by
email to complete an anonymous online survey, which
contained questions about hereditary PCa and their
attitudes towards PCa case-ﬁnding and screening.
109 urologists (31%), 69 GPs (23%) and 46 CGs (31%)
completed the survey. CGs had the most accurate knowl-
edge of hereditary PCa. All but 1 CG mentioned at least
one inherited trait with PCa, compared to only 25% of
urologists and 9% of GPs. CGs hardly ever counseled men
about PCa testing. Most urologists and GPs discuss pos-
sible risks and beneﬁts before testing for PCa with PSA.
Remarkably, 35–40% of them do not take family history
into consideration. Knowledge of urologists and GPs about
heredity and PCa is suboptimal. Hence, PCa counseling
might not be optimal for men with a positive family his-
tory. Multidisciplinary guidelines on this topic should be
developed to optimize personalized counseling.
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A positive family history of prostate cancer (PCa) is an
established risk factor for PCa. First-degree relatives of
affected men have a 2–3 fold increased risk of PCa [1].
When 3 or more ﬁrst-degree relatives are affected (or at least
2 ﬁrst-degree relatives before the age of 55 years), the
family is considered a ‘Hereditary Prostate Cancer’ (HPC)
family according to the so-called Johns Hopkins or Carter
criteria [2]. An estimated 5–10% of PCa has a genetic cause.
Yet, only a few very rare high-penetrance gene mutations
have been identiﬁed to cause HPC [3]. In recent years,
genome-wide association studies have added approximately
40 low-penetrance genetic polymorphisms that are associ-
ated with an increased risk of PCa [4, 5]. Several poly-
morphisms have also been identiﬁed that are associated with
serum prostate-speciﬁc antigen (PSA), the most commonly
used marker for early detection of PCa [6, 7]. An ongoing
matter of debate is whether PSA testing should be used for
population-wide screening [8]. In a population-based setting,
the European Randomized Study of Screening for Prostate
Cancer (ERSPC) showed a decrease in PCa mortality of
31% in the screening arm after correction for non-attendance
and contamination. However, this mortality reduction coin-
cided with considerable overtreatment [9, 10]. By contrast,
the Prostate, Lung, Colorectal and Ovarian Cancer Screen-
ing Trial (PLCO), found no effect of PSA screening on
mortality [11], but suffered from methodological problems
which severely hamper interpretation of the results [12].
Previous studies into the effectiveness of PSA sceening
in men with an increased risk due to family history have
yielded largely inconsistent results. These range from a
marked beneﬁt for men in high-risk PCa families (partic-
ularly for families with early onset PCas) to a decreased
risk of PCa for non-affected men in HPC families [13, 14].
The increasing use of PSA testing in the general population
has also had an important inﬂuence on men with a family
history of PCa. Men with a positive family history are
relatively more active in pursuing PSA testing than men in
the general population. This has led to an increased
detection of mainly of small localized tumors [15].
To guide the public and physicians in translating the
results of the ERSPC and PLCO into clinical practice, the
Dutch Association of Urology (NVU) and the Dutch Col-
lege of General Practitioners (NHG) concurrently released
a policy statement in March 2009. This statement referred
men to a website (http://www.prostaatwijzer.nl/) with
information about PCa and PSA testing and advised them
to consult their GP for further counseling [16]. It did,
however, not discuss dealing with a family history of PCa
or HPC. To date, in absence of ofﬁcial internationally
accepted guidelines, the advice is to attempt to distinguish
genetic predisposition-based families with multiple PCa
cases from ascertainment-based multiple-case families and
offer PCa screening only to the former [13].
This study assessed the knowledge of Dutch urologists,
general practitioners (GPs) and clinical geneticists (CGs)
about HPC and PCa as a phenotype in hereditary syn-
dromes. Furthermore, their ‘post-ERSPC’ attitude towards
PCa testing and the role of family history in clinical
decision-making about PCa testing were assessed. To our
knowledge, this is the ﬁrst study to investigate this in dif-
ferent professions that counsel men about PCa testing.
Materials and Methods
After publication of the results of the ERSPC and PLCO
and the statements of the NVU and NHG, an online survey
was developed [17]. This survey, targeted at Dutch urolo-
gists, GPs and CGs, contained questions about HPC and
assessed the participants’ general attitude towards PCa
testing. In addition to this, it inquired into the role that
family history played in the physician’s daily clinical
practice regarding PCa testing. The survey also included
case descriptions of a man requesting to be tested for PCa.
This ﬁctitious man presented at different ages, in absence
of family history and physical complaints. The survey
could be completed anonymously.
In January 2010, all Dutch urologists (n = 351), clinical
oncogeneticists (n = 32), CGs in training (n = 50) and
genetic counselors (n = 68) were invited by e-mail from
their respective professional associations. GPs in the region
of the Comprehensive Cancer Centre East (CCCE) who
were enlisted to receive the CCCE’s e-newsletter (n = 300)
were invited by e-mail.
For statistical analysis, descriptive analyses were per-
formed, stratiﬁed by profession. Because of small numbers,
clinical oncogeneticists, CGs in training and genetic
counselors were pooled into one stratum (CGs). Chi-square
testing was used to test for differences between profes-
sions. Participants who never counseled men about PCa
testing were excluded from the analysis.
Results
In total, 225 surveys were completed (overall response rate
28%). These were submitted by 109 urologists (31%), 69
GPs (23%) and 46 CGs (31%). One pediatric urologist and
two CGs were excluded from analyses because they never
counseled men for PCa testing. Occasionally, participants
did not complete all questions, causing small differences in
the subtotals for different questions. Of the urologists, 66%
(71/107) counseled men about PCa testing at least once a
week and 93% (100/107) did this at least once a month.
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123In comparison, 85% of the GPs (59/69) did this at least
once a month, as opposed to only 2% (1/44) of the CGs.
By contrast, the CGs had the most accurate knowledge
of the HPC criteria: 72% (31/43) correctly selected the
minimum of three affected ﬁrst-degree relatives for the
criterion that is most frequently fulﬁlled (Table 1). In
comparison, only 36% (38/105) of the urologists and 18%
(12/66) of the GPs correctly selected this criterion
(P\0.001). A majority of the GPs (59%) indicated not to
know this deﬁnition. CGs were also best informed about
the number of affected ﬁrst-degree relatives with a PCa
diagnosis before 55 years of age to meet the deﬁnition of
HPC, although the differences between the groups were
smaller. The third deﬁnition of HPC, i.e., three consecutive
generations with PCa, was known to only a few
participants.
Almost all CGs (41/42, 98%) listed at least one inherited
trait with PCa as part of the phenotype, compared to only
24% (25/103) of the urologists and 9% (6/66) of the GPs.
The most frequently mentioned traits were the BRCA2 gene
mutation (n = 60), the BRCA1 gene mutation (n = 40) and
Lynch syndrome (n = 10). The rare HPC1, HPCX, MSR1,
RNASEL and HPC2/ELAC2 mutations were sporadically
mentioned.
Urologists had the least reservations towards PCa testing
in a man with no physical complaints and no family history
of PCa: 46% (32/69) of the GPs and 49% (22/45) of the
CGs preferred to refrain from testing unless there were
strong reasons to test (Table 2), as compared to 31% (33/
108) of the urologists. For a man presenting at 55 and
75 years of age, urologists and GPs gave similar answers.
Between 70 and 80% of them would ﬁrst inform him about
the possible beneﬁts and risks of PCa testing. CGs were
more inclined not to test for PCa. At 45 years of age, more
physicians in all groups would not test for PCa.
Age played a role when considering PCa testing. Of the
urologists, 70% reported to use age limits, with 45 years as
the mean and median lower age limit. This lower age limit
was higher for GPs (60% reported age limits) and CGs
(30% reported age limits), with 50 years of age being the
median lower age limit. The median maximum age limit
was 80 years (mean 77) for urologists and GPs, compared
to 75 years (mean 74) for CGs. CGs always took family
history into consideration when deciding whether or not to
test for PCa. By contrast, 35–40% of urologists and GPs
answered that family history would not inﬂuence the
decision whether or not to test for PCa (Table 3). This did
not vary between physicians with different general atti-
tudes towards PSA testing (P = 0.47 for the urologists and
P = 0.78 for the GPs), as was assessed in a previous
question.
A majority of the urologists (76%) knew the ERSPC and
PLCO results, compared to only 14 and 8% of CGs and
GPs, respectively. Ninety-two percent (75/82) of the urol-
ogists who knew the studies found the ERSPC results more
valuable. The statements of NVU and NHG, advising men
to visit the website and consult the GP if further counseling
was needed, were better known than the results of the tri-
als: 85% (92/108) of the urologists and 59% (41/69) of the
GPs was familiar with the statements. Of them, 12% (11/
91) of the urologists and 24% (10/41) of the GPs did not
agree with the statements. Only 2 of the 43 CGs (5%) were
familiar with the statements.
Discussion
A positive family history of PCa is an important risk factor
for PCa and the balance between pros and cons of PSA
testing may be different in men with affected relatives. It is
therefore remarkable that urologists and GPs are poorly
informed about HPC. Only one in three urologists and one
Table 1 Responses to the question ‘‘What is the minimum number of
relatives with prostate cancer to meet the Carter criteria for hereditary
prostate cancer (HPC)?’’
Urologists GPs CGs
Number of affected ﬁrst-degree relatives (all ages)

Two 35 (33%) 9 (14%) 1 (2%)
Three 38 (36%) 12 (18%) 31 (72%)
Four 1 (1%) 2 (3%) 2 (5%)
[Four 3 (3%) 0 (0%) 1 (2%)
Don’t know 15 (14%) 39 (59%) 7 (16%)
Not a criterion 13 (12%) 4 (6%) 1 (2%)
Total 105 66 43
Number of affected ﬁrst-degree relatives (diagnosis\55 years of
age)

Two 72 (68%) 33 (48%) 34 (76%)
Three 6 (6%) 0 (0%) 3 (7%)
Four 1 (1%) 1 (1%) 0 (0%)
[Four 5 (5%) 2 (3%) 0 (0%)
Don’t know 12 (11%) 32 (46%) 7 (16%)
Not a criterion 10 (9%) 1 (1%) 1 (2%)
Total 106 69 45
Number of consecutive generaties with prostate cancer

Two 10 (10%) 10 (15%) 9 (21%)
Three 15 (15%) 6 (9%) 5 (11%)
Four 3 (3%) 1 (2%) 1 (2%)
[Four 2 (2%) 1 (2%) 0 (0%)
Don’t know 25 (25%) 39 (58%) 10 (23%)
Not a criterion 44 (44%) 10 (15%) 19 (43%)
Total 99 67 44
 P B 0.001 for differences between the physician groups
Correct answers are italicized
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123in ﬁve GPs is familiar with the criteria for HPC. Almost
60% of the GPs indicated not to know the deﬁnition. CGs
were better informed, but they hardly ever counsel men
about PCa testing.
The BRCA1 gene mutation was frequently selected as an
inherited trait with PCa as part of the phenotype. The evi-
dence for an increased risk of PCa due to a BRCA1 gene
mutation is quite weak, though. By contrast, for BRCA2 gene
mutations (selected by 14 urologists and all 42 CGs) there is
fairly solid evidence of familial clustering of aggressive PCa
[18, 19].Lynch syndrome was alsoselected10 times,7 times
of which by urologists. Recently, an elevated risk of PCa for
carriers of a mismatch-repair gene mutation was indeed
found [20]. This has, however, not been conﬁrmed in other
studies, so it remains unclear whether the physicians who
selected Lynch syndrome are correct. It should be noted that
urologists and GPs hardly ever counsel patients with an
elevated PCa risk based on these inherited traits.
In general, urologists reported the least reservations
towards PCa testing and would test at a younger age than
GPs and CGs. However, the majority of urologists and GPs
stated to ﬁrst discuss the risks and beneﬁts of PSA testing
and only test if a man would still want to be tested. So,
even though 41% of GPs was not familiar with the state-
ments regarding PCa testing and 92% of them did not know
the ERSPC and PLCO results, they adhered just as well to
the guidelines as the urologists. Participants who disagreed
with the NVU/NHG statements, mostly indicated that the
statements lacked attention for patients’ preferences.
In contrast with the urologists and GPs, CGs would
more often not test for PCa. This might be explained by the
fact that the CGs mainly have an advisory role and refer
their patients to a GP or urologist for PCa testing. CGs
hardly ever counsel men about PCa testing, as there is no
frequently occurring genetic defect known to cause PCa.
This may change, however, when more data become
available about the risk of PCa among BRCA2 carriers.
An international study is currently examining this risk
(www.impact-study.co.uk).
One of the most striking observations might be that
more than one in three urologists and GPs would not take
family history into account when deciding whether or not
to test a man for PCa. Intuitively, one would think that men
with a positive family history, and thus a higher a priori
Table 2 Responses to the question ‘‘Would you test this man for PCa?’’ regarding a man with no physical complaints/no family history of PCa,
requesting to be tested for PCa
Age at presentation Test for prostate cancer Urologists GPs CGs
General attitude
a Will test, unless… 35 (32%) 13 (19%) 3 (7%)
Will not test, unless… 33 (31%) 32 (46%) 22 (49%)
Leave choice to patient 37 (34%) 22 (32%) 9 (20%)
Other* 3 (3%) 2 (3%) 11 (25%)
45 years of age Yes 20 (19%) 5 (7%) 1 (2%)
No 12 (11%) 18 (26%) 28 (64%)
First discuss pros and cons of prostate cancer testing 75 (70%) 46 (67%) 15 (34%)
55 years of age
b Yes 29 (27%) 16 (23%) 1 (2%)
No 0 (0%) 1 (1%) 16 (36%)
First discuss pros and cons of prostate cancer testing 79 (73%) 52 (75%) 27 (61%)
75 years of age
c Yes 21 (19%) 10 (15%) 9 (21%)
No 8 (7%) 3 (4%) 14 (33%)
First discuss pros and cons of prostate cancer testing 79 (73%) 56 (81%) 20 (47%)
* Answers under ‘‘Other’’: most often (8/11) CGs indicated not to perform this kind of testing themselves, but would refer the man to their GP
a P\0.001 for differences between the physician groups
b No signiﬁcant difference between urologists and GPs; P = 0.40
c No signiﬁcant difference between urologists and GPs; P = 0.45
Table 3 Responses to the question (A) ‘‘Does family history play a
role in the decision whether or not to test a man for PCa?’’ and the
follow-up question (B) ‘‘How extensively do you inquire about the
family history?’’
Urologists GPs CGs
A. Does family history play a role?
Yes 67 (62%) 44 (65%) 40 (98%)
No 41 (38%) 24 (35%) 1 (2%)
Total 108 68 41
B. Extent of inquiring about the family history?
Only PCa 29 (43%) 16 (37%) 0 (0%)
PCa and other malignancies 38 (57%) 27 (63%) 40 (100%)
Total 67 43 40
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123risk of PCa, would beneﬁt more from PSA screening.
Arguing against this is that HPC cases do not seem to differ
from sporadic cases with respect to Gleason scores and
PCa-speciﬁc survival [21, 22]. Even more so, screening
programs amongst non-affected men in HPC families have
shown that the chance of ﬁnding PCa in non-affected men
in HPC families is low [13].
Although we did not address this in our study, when a
man requesting PCa testing does have, e.g., an affected
brother, he will very likely be tested, not in the least for
reasons of anxiety management. However, whether this is
beneﬁcial, is doubtful. To better guide physicians in this
matter, an addendum to PCa guidelines should be devel-
oped in a multidisciplinary collaborative effort, describing
how to deal with PCa testing in case of a positive family
history and HPC. The conclusion from a previous study to
assess the extent and nature of the family history (predis-
position-based vs. ascertainment-based) might well serve
as a starting point for such a guideline [13]. In addition to
this, the use of decision aids, e.g., the SWOP-PRI should be
promoted [23], as they already include the effect of family
history in the risk estimates.
The results of this study should be interpreted with some
caution. Although the responder groups were reasonably
large in absolute numbers, the response rate was only 31%
at best (for urologists and CGs). Hence, it is difﬁcult to
extrapolate the results to all Dutch physicians providing
PCa counseling. Even more so, if physicians with more
interest in this topic completed the survey more often, the
results regarding knowledge about HPC and adherence to
guidelines might be overoptimistic. On the other hand,
intuitively physicians who take care of most of the coun-
seling are most eager to complete the survey. It is also
important to bear in mind that the results may not easily be
extrapolated to other countries as they may be inﬂuenced
by the health care system. In The Netherlands, e.g., men
cannot visit a urologist without a referral from their GP.
In conclusion, the majority of urologists and GPs
adhered to PCa testing guidelines. However, these guide-
lines do not include family history and many physicians
indicated not to consider family history. Hence, PCa
counseling might not be optimal for men with a positive
family history. We propose that additional guidelines on
this topic are developed in a multidisciplinary effort to
optimize counseling.
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